home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2896.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
50 lines
Document 2896
DOCN M94A2896
TI Randomized comparative trial of ZDV+ddI vs ZDV+ddC on short-term safety
and laboratory markers in subjects with CD4s of 50 to 350/microL.
Canadian HIV Trials Network.
DT 9412
AU Montaner JS; Srour L; Singer J; Cassol S; O'Shaughnessy MV; Schechter
MT; Bristol-Myers & Squibb, Canada.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):20 (abstract no. 055B). Unique
Identifier : AIDSLINE ICA10/94369679
AB OBJECTIVE: To compare the short term safety and surrogate marker effects
of ZDV/ddI vs. ZDV/ddC. METHODS: HIV+ patients tolerant of ZDV > or =
400 mg/d were eligible if they were ddI and ddC naive and had CD4 counts
of 50 to 350/mm3. Eligible patients could select between the open arm of
the study, namely choosing between ZDV+ddI and ZDV+ddC, or randomization
to either regimen in full doses on an open label basis. Drugs were made
available free of charge for both arms of the study. Patients were
stratified according to whether they had previously treated with ZDV and
to CD4 count at baseline (< or = 100 and > or = 100/mm3). Randomized
patients were seen at 1, 2, 3, 5 and 7 months for assessment of clinical
status, adverse effects, CD4 count, P24 antigen and quantitative plasma
HIV-RNA PCR. RESULTS: A total of 136 patients have been randomized:
67-ZDV+ddI; 69-ZDV+ddC. 92% were male, 75% gay or bisexual; mean age =
38. Only 1.5% of patients had AIDS at entry. Mean baseline CD4 count was
230. Change in CD4 count over time for patients remaining on assigned
study therapy, to date, is shown in the figure. Both groups experienced
a significant rise in CD4 count. Although there was a trend in favour of
ZDV/ddI, this has not reached statistical significance. Adverse events
resulted in reduction or discontinuation in 26% and 20% of ddI and ddC
treated patients, respectively. This was most commonly due to peripheral
neuropathy (ddI = 6; ddC = 5). P24 antigen and quantitative plasma
HIV-RNA PCR results are pending. CONCLUSIONS: Our preliminary analysis
demonstrates that short term use of ZDV+ddI or ZDV+ddC is associated
with a significant increase in CD4 count. Although a trend was found in
favor of ZDV/ddI, this did not reach statistical significance. Short
term safety profile was similar between both regimens. P24 antigen and
quantitative plasma HIV-RNA PCR results are pending. TABULAR DATA, SEE
ABSTRACT VOLUME.
DE Acquired Immunodeficiency Syndrome/DRUG THERAPY Adult Comparative
Study Didanosine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug
Therapy, Combination Female Human HIV Seropositivity/*DRUG THERAPY
Male Support, Non-U.S. Gov't T4 Lymphocytes
Zalcitabine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS
Zidovudine/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS CLINICAL TRIAL
MEETING ABSTRACT RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).